How many Hepatitis-C deaths does it take to make a billion dollars for a drug company?


10 May 2017

Shareholders of American pharmaceutical giant Gilead are meeting in California today to review the work and profits of the company. We’ve done some of the maths for them: Every 79 seconds* someone in the world dies of hepatitis C. And in that same amount of time, Gilead makes $26,068* from selling the cure for hepatitis C.

In late 2013, Gilead launched Sofosbuvir – a new wonder drug that cures almost all cases of hepatitis C. That means that we could make some big steps towards eradicating the disease, which globally affects more than 71 million people and kills close to 400,000 people a year.

Sofosbuvir has provided a new lifeline for millions of people. But there’s one problem. Gilead has set prices so high that only a small fraction of people can afford it. In the UK, NHS England has had to ration the use of Sofosbuvir because of costs and can currently only treat less than 1 in 20 patients. And the situation is even more bleak in many poor and middle-income countries.

The cost price of producing it is as low as a few hundred pounds per treatment, but the NHS is currently paying up to £78,000. So why is this drug so expensive? Thanks to global patent laws, Gilead has a 20-year monopoly on the drug and can charge what they want, holding hepatitis C patients as hostages in order to rake in tens of billions of dollars in revenues.

Since 2014

Patent laws are supposed to help incentivise research and development by ensuring profits for new drugs. But Gilead did not invent Sofosbuvir. The research for the drug was partly funded by American tax-payers and the investment that Gilead made in buying the rights for the drug was more than made back in their first year of its sale. So most of the money you pay for the drug now goes to marketing and to paying dividends to the shareholders gathering in California right now.

The case of Gilead and Sofosbuvir is far from unique. Across the world, hundreds of millions of people are priced out of accessing the medicines they need by big pharmaceutical companies with monopolies over essential medicines. It’s estimated that ten million people across the global south died from AIDS-related diseases while big drug companies tried to block the production of ‘generic’ versions of drugs that could be used to cheaply treat patients. In the UK the annual NHS drug spending has gone up by £3.8 billion in the last 5 years and the NHS increasingly has to reject or ration new drugs because of their costs, leaving patients without access to new treatments.

It’s high time for policy makers to realise that the current system isn’t working for people here in the UK and around the world. We clearly can’t trust giant companies with our health so why are we handing them control over essential medicines when most innovative research is funded by us in the first place?

* A breakdown of our calculations can be found here.

Photo: The Platform for those affected by hepatitis C march in Madrid in 2015, with a banner calling for treatment for everyone. UPYD/Flickr.

Blog

These schools wouldn’t be good enough for kids in the UK, so stop promoting them overseas


22 November 2017
Aid

“Unsanitary learning conditions”, “unqualified teachers”, “poor quality education”, “unaffordable”. These are just some of the damning terms used to describe schools across Africa run by Bridge International Academies, a private for-profit company that provides ‘low cost’ private education.

How Liam Fox read 60,000 comments on the trade consultation in a few hours


22 November 2017

Liam Fox must be a very fast reader. Superhuman in fact. Because just hours after the ‘consultation’ on the trade white paper closed, the government proposed a new Trade Bill.

The tabloids’ aggressive response to Stop Funding Hate’s Paperchase victory shows they’re feeling the heat


21 November 2017

The last few days have seen the question of advertising in the hate-filled right-wing media back in the news after a partnership between Paperchase and the Daily Mail on Saturday led to a customer backlash.